Top ▲

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tyrosine kinase 2

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 2269

Nomenclature: tyrosine kinase 2

Abbreviated Name: Tyk2

Family: Janus kinase (JakA) family

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 1187 19p13.2 TYK2 tyrosine kinase 2
Mouse - 1184 9 A3 Tyk2 tyrosine kinase 2
Rat - 1186 8q13 Tyk2 tyrosine kinase 2
Previous and Unofficial Names Click here for help
JTK1
Database Links Click here for help
Alphafold P29597 (Hs), Q9R117 (Mm)
BRENDA 2.7.10.2
CATH/Gene3D 1.20.80.10, 3.30.505.10
ChEMBL Target CHEMBL3553 (Hs), CHEMBL2321619 (Mm)
Ensembl Gene ENSG00000105397 (Hs), ENSMUSG00000032175 (Mm), ENSRNOG00000032948 (Rn)
Entrez Gene 7297 (Hs), 54721 (Mm), 100361294 (Rn)
Human Protein Atlas ENSG00000105397 (Hs)
KEGG Enzyme 2.7.10.2
KEGG Gene hsa:7297 (Hs), mmu:54721 (Mm), rno:100361294 (Rn)
OMIM 176941 (Hs)
Orphanet ORPHA159075 (Hs)
Pharos P29597 (Hs)
RefSeq Nucleotide NM_003331 (Hs), NM_001205312 (Mm), NM_001257347 (Rn)
RefSeq Protein NP_003322 (Hs), NP_001192241 (Mm), NP_001244276 (Rn)
SynPHARM 80438 (in complex with JAK inhibitor I)
85284 (in complex with tofacitinib)
UniProtKB P29597 (Hs), Q9R117 (Mm)
Wikipedia TYK2 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Non-phosphorylated TYK2 kinase with CMP6.
PDB Id:  3NZ0
Ligand:  JAK inhibitor I
Resolution:  2.0Å
Species:  Human
References:  47
Image of receptor 3D structure from RCSB PDB
Description:  Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
PDB Id:  3LXP
Ligand:  tofacitinib
Resolution:  1.65Å
Species:  Human
References:  8
Image of receptor 3D structure from RCSB PDB
Description:  Tyk2 with compound 23
PDB Id:  6DBM
Ligand:  brepocitinib
Resolution:  2.368Å
Species:  Human
References:  17
Enzyme Reaction Click here for help
EC Number: 2.7.10.2

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
BMS-986202 Small molecule or natural product Hs Inhibition 10.7 pKi 28
⤷ pKi 10.7 (Ki 2x10-11 M) [28]
Description: Binding affinity for Tyk2 JH2 domain
izencitinib Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 9.0 – 10.0 pKi 23
⤷ pKi 9.0 – 10.0 (Ki 1x10-9 – 1x10-10 M) [23]
nezulcitinib Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.6 pKi 30
⤷ pKi 8.6 (Ki 2.5x10-9 M) [30]
GDC-0214 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.5 pKi 13
⤷ pKi 8.5 (Ki 3.15x10-9 M) [13]
delgocitinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.8 pKi 44
⤷ pKi 7.8 (Ki 1.4x10-8 M) [44]
Description: In an assay using the kinase domain of the recombinant human enzyme, a biotinylated peptide substrate, and [33P]ATP.
BMS-986202 Small molecule or natural product Hs Inhibition 9.7 pIC50 28
⤷ pIC50 9.7 (IC50 1.9x10-10 M) [28]
cerdulatinib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 9.3 pIC50 10
⤷ pIC50 9.3 (IC50 5x10-10 M) [10]
JAK inhibitor I Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 9.0 pIC50 16
⤷ pIC50 9.0 (IC50 1x10-9 M) [16]
SAR-20347 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.9 – 9.2 pIC50 52
⤷ pIC50 9.2 (IC50 6x10-10 M) [52]
Description: In a 33P-ATP assay.
pIC50 7.9 (IC50 1.3x10-8 M) [52]
Description: In a TR-FRET assay.
compound 29 [Moslin et al., 2017] Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.4 pIC50 34
⤷ pIC50 8.4 (IC50 4x10-9 M) [34]
Description: Measuring binding to the JH2 pseudokinase domain of human TYK2.
ruxolitinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.5 – 9.3 pIC50 9,21
⤷ pIC50 9.3 (IC50 5.5x10-10 M) [21]
pIC50 7.5 (IC50 3x10-8 M) [9]
peficitinib Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.3 pIC50 25
⤷ pIC50 8.3 (IC50 5x10-9 M) [25]
lorpucitinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.1 pIC50 27
⤷ pIC50 8.1 (IC50 7.4x10-9 M) [27]
Description: Determined in a biochemical high-throughput mass spectrometry (HTMS) assay.
TYK2 inhibitor 14l Small molecule or natural product Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 8.1 pIC50 56
⤷ pIC50 8.1 (IC50 9x10-9 M) [56]
zotiraciclib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.8 pIC50 19
⤷ pIC50 7.8 (IC50 1.4x10-8 M) [19]
ropsacitinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.8 pIC50 18
⤷ pIC50 7.8 (IC50 1.5x10-8 M) [18]
momelotinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.7 pIC50 2
⤷ pIC50 7.7 (IC50 1.99x10-8 M) [2]
ilginatinib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.7 pIC50 36
⤷ pIC50 7.7 (IC50 2.2x10-8 M) [36]
brepocitinib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.6 pIC50 17
⤷ pIC50 7.6 (IC50 2.3x10-8 M) [17]
PF-06263276 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.5 pIC50 26
⤷ pIC50 7.5 (IC50 2.97x10-8 M) [26]
JAK inhibitor 17b Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.4 pIC50 15
⤷ pIC50 7.4 (IC50 3.94x10-8 M) [15]
compound 13 [PMID: 34333981] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.3 pIC50 14
⤷ pIC50 7.3 (IC50 4.8x10-8 M) [14]
CEE321 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.3 pIC50 45
⤷ pIC50 7.3 (IC50 5x10-8 M) [45]
delgocitinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.2 pIC50 37
⤷ pIC50 7.2 (IC50 5.8x10-8 M) [37]
baricitinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.2 pIC50 9
⤷ pIC50 7.2 (IC50 6.1x10-8 M) [9]
BMS-911543 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.2 pIC50 40
⤷ pIC50 7.2 (IC50 6.6x10-8 M) [40]
compound 6 [PMID: 34333981] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.2 pIC50 14
⤷ pIC50 7.2 (IC50 6.7x10-8 M) [14]
JAK inhibitor 20a Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.1 pIC50 15
⤷ pIC50 7.1 (IC50 7.37x10-8 M) [15]
oclacitinib Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 7.1 pIC50 4
⤷ pIC50 7.1 (IC50 7.51x10-8 M) [4]
compound 13ac [PMID: 33256400] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.1 pIC50 55
⤷ pIC50 7.1 (IC50 7.5x10-8 M) [55]
zasocitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition >7.0 pIC50 32
⤷ pIC50 >7.0 (IC50 <1x10-7 M) [32]
Description: Inhibition of IL-12 Induced STAT4 phosphorylation as mediated by Tyk2/JAK2 heterodimeric complex
compound 25ap [PMID: 37796543] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.0 pIC50 57
⤷ pIC50 7.0 (IC50 9.9x10-8 M) [57]
zemprocitinib Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 6.9 pIC50 50
⤷ pIC50 6.9 (IC50 1.19x10-7 M) [50]
LASW1393 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 6.9 pIC50 3
⤷ pIC50 6.9 (IC50 1.3x10-7 M) [3]
PF-956980 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.9 pIC50 20
⤷ pIC50 6.9 (IC50 1.28x10-7 M) [20]
fedratinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.8 pIC50 31
⤷ pIC50 6.8 (IC50 1.5x10-7 M) [31]
solcitinib Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 6.7 pIC50 5
⤷ pIC50 6.7 (IC50 2.19x10-7 M) [5]
tofacitinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 6.3 pIC50 9
⤷ pIC50 6.3 (IC50 4.89x10-7 M) [9]
Description: In a biochemical enzyme assay.
filgotinib Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 5.6 – 6.9 pIC50 9,48
⤷ pIC50 6.9 (IC50 1.16x10-7 M) [48]
pIC50 5.6 (IC50 2.6x10-6 M) [9]
compound 30 [PMID: 37057760] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.1 pIC50 41
⤷ pIC50 6.1 (IC50 7.804x10-7 M) [41]
cenacitinib Small molecule or natural product Hs Inhibition >6.0 pIC50 33
⤷ pIC50 >6.0 (IC50 <1x10-6 M) [33]
Description: Binned value determined as inhibition in aJAK1 /TYK2 stimulated STAT1 phosphorylation assay
golidocitinib Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 5.6 pIC50 43
⤷ pIC50 5.6 (IC50 2.8x10-6 M) [43]
Description: Inhbition of TYK2 enzymatic activity.
upadacitinib Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 5.3 pIC50 49
⤷ pIC50 5.3 (IC50 4.7x10-6 M) [49]
JAK3 inhibitor 32 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition <5.0 pIC50 6
⤷ pIC50 <5.0 (IC50 >1x10-5 M) [6]
JAK3 inhibitor 34 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition <5.0 pIC50 6
⤷ pIC50 <5.0 (IC50 >1x10-5 M) [6]
Inhibitor Comments
The IC50 for decernotinib vs. TYK2 is >10 μM [9].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
deucravacitinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 10.7 pKi 53
⤷ pKi 10.7 (Ki 2x10-11 M) [53]
Description: Determined in a Morrison titration by varying the concentration of the fluorescent probe in the TYK2 JH2 assay.
deucravacitinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 9.7 pIC50 53
⤷ pIC50 9.7 (IC50 2x10-10 M) [53]
Description: Binding to TYK2's JH2 pseudokinase domain in a biochemical binding assay.
TYK2 inhibitor 18 [WO2023227946] Small molecule or natural product Hs Inhibition >7.5 pIC50 38
⤷ pIC50 >7.5 (IC50 <3x10-8 M) [38]
Description: Inhibition of TYK2-mediated induction of IL-23 and IFNα production in cellular reporter gene assays.
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
SJ988497 Small molecule or natural product Click here for species-specific activity table Hs Binding 9.3 pKd 7
⤷ pKd 9.3 (Kd 5.4x10-10 M) [7]
TYD-68 Small molecule or natural product Immunopharmacology Ligand Hs Binding - - 54
⤷ PROTAC [54]
DiscoveRx KINOMEscan® screen Click here for help
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 12,51
Key to terms and symbols Click column headers to sort
Target used in screen: TYK2(JH1domain-catalytic)
Ligand Sp. Type Action Value Parameter
ruxolitinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 9.1 pKd
tofacitinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.3 pKd
JNJ-28312141 Small molecule or natural product Hs Inhibitor Inhibition 8.2 pKd
lestaurtinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 7.8 pKd
fedratinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.3 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.1 pKd
dovitinib Small molecule or natural product Hs Inhibitor Inhibition 6.8 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 6.8 pKd
alvocidib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 6.7 pKd
Target used in screen: TYK2(JH2domain-pseudokinase)
Ligand Sp. Type Action Value Parameter
alvocidib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.5 pKd
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 7.0 pKd
sunitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 6.4 pKd
fedratinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 6.3 pKd
JNJ-28312141 Small molecule or natural product Hs Inhibitor Inhibition 6.3 pKd
MLN-120B Small molecule or natural product Immunopharmacology Ligand Hs Inhibitor Inhibition 6.3 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 6.3 pKd
SU-14813 Small molecule or natural product Hs Inhibitor Inhibition 6.1 pKd
TG-100-115 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 6.1 pKd
lestaurtinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 6.0 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen Click here for help
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx

Reference: ...1
Key to terms and symbols Click column headers to sort
Target used in screen: nd/TYK2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
JNJ-7706621 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 0.9
K-252a Small molecule or natural product Hs Inhibitor Inhibition 0.9
JAK inhibitor I Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 1.5
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 1.9
Gö 6976 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 2.6
SB 218078 Small molecule or natural product Hs Inhibitor Inhibition 4.3
Cdk2 inhibitor IV Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 5.0
Cdk1/2 inhibitor III Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 5.1
IKK-2 inhibitor IV Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 6.3
midostaurin Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.3
Displaying the top 10 most potent ligands  View all ligands in screen »
Immunopharmacology Comments
TYK2 was the first member of the Janus kinase family to be identified. It associates with the cytoplasmic domain of type I and type II cytokine receptors, where it phosphorylates receptor subunits and facilitates signalling downstream of the receptors for the p40-containing cytokines IL-12 and IL-23 via activation of STAT-dependent transcription factors. It also mediates Type I IFN-driven responses [42]. TYK2 activity mediates cytokine-driven immune and pro-inflammatory signalling pathways that are key components in the cycle of chronic inflammation that drives the pathophysiology of immune-mediated diseases including psoriasis [24] and arthritic psoriasis, systemic lupus erythematosus and inflammatory bowel diseases.

Small molecules that inhibit TYK2 are being actively developed as novel therapeutics for the above conditions [22,35]. TYK2 selectivity has been achieved by targeting the protein's pseudokinase (Jak homology 2 or JH2) domain [29,46], rather than the functional kinase (or JH1) domain which shares a high degree of homology across all members of the Janus kinase family and offers little selectivity. Identified molecules act as negative allosteric modulators (NAM) of TYK2 activity. One particular example of a clinical candidate TYK2 NAM is deucravacitinib (BMS-986165), which is an orally active compound that has progressed to Phase 3 clinical evaluation in patients with psoriasis [39], and is the first truly TYK2 selective inhibitor. Clinical trials are in earlier stages for a spectrum of chronic autoimmune diseases. Click here to link to ClinicalTrials.gov's full list of BMS-986165 studies. Nimbus Therapeutics are also developing allosteric TYK2 inhibitors (claimed in their patent WO2016138352 [11]), although no clinical leads have been disclosed (July 2021).
Immuno Process Associations
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes
GO:2000318 positive regulation of T-helper 17 type immune response NAS
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 3 GO processes
GO:0032819 positive regulation of natural killer cell proliferation IDA
GO:0042102 positive regulation of T cell proliferation IDA
GO:0051142 positive regulation of NK T cell proliferation IDA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 2 GO processes
GO:0042102 positive regulation of T cell proliferation IDA
GO:0051142 positive regulation of NK T cell proliferation IDA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 9 GO processes
GO:0019221 cytokine-mediated signaling pathway IBA
GO:0032729 positive regulation of type II interferon production IDA
GO:0032740 positive regulation of interleukin-17 production NAS
GO:0035722 interleukin-12-mediated signaling pathway IDA
GO:0038155 interleukin-23-mediated signaling pathway IDA
GO:0038196 type III interferon-mediated signaling pathway NAS
GO:0060333 type II interferon-mediated signaling pathway IDA
GO:0060337 type I interferon-mediated signaling pathway IDA
GO:0140105 interleukin-10-mediated signaling pathway IDA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 4 GO processes
GO:0032819 positive regulation of natural killer cell proliferation IDA
GO:0042102 positive regulation of T cell proliferation IDA
GO:0051142 positive regulation of NK T cell proliferation IDA
GO:2000318 positive regulation of T-helper 17 type immune response NAS
Immuno Process:  Inflammation
GO Annotations:  Associated to 3 GO processes
GO:0038196 type III interferon-mediated signaling pathway NAS
GO:0060333 type II interferon-mediated signaling pathway IDA
GO:0060337 type I interferon-mediated signaling pathway IDA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 3 GO processes
GO:0042102 positive regulation of T cell proliferation IDA
GO:0051142 positive regulation of NK T cell proliferation IDA
GO:2000318 positive regulation of T-helper 17 type immune response NAS
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Immunodeficiency 35; IMD35
Synonyms: Autosomal recessive hyper-IgE syndrome due to TYK2 deficiency [Orphanet: ORPHA331226]
Tyrosine kinase 2 deficiency
OMIM: 611521
Orphanet: ORPHA331226
Disease:  Juvenile rheumatoid factor-negative polyarthritis
Orphanet: ORPHA85408
Disease:  Oligoarticular juvenile arthritis
Orphanet: ORPHA85410

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]

2. Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, Seifert M, Posch W, Nairz M, Maciejewski P et al.. (2017) Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood, 129 (13): 1823-1830. [PMID:28188131]

3. Bach J, Eastwood P, González J, Gómez E, Alonso JA, Fonquerna S, Lozoya E, Orellana A, Maldonado M, Calaf E et al.. (2019) Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases. J Med Chem, 62 (20): 9045-9060. [PMID:31609613]

4. Berlinski PJ, Birchmeier MJ, Bowman JW, Gonzales AJ, Kamerling SG, Mann DW, Mitton-Fry MJ. (2010) Pyrrolo[2,3-d]pyrimidine compounds. Patent number: WO2010020905. Assignee: Pfizer Inc.. Priority date: 20/08/2008. Publication date: 25/02/2010.

5. Blanc J. (2010) Novel compound useful for the treatment of degenerative and inflammatory diseases. Patent number: WO2010149771. Assignee: Galapagos Nv, Menet, Christel Jeanne Marie. Priority date: 26/06/2009. Publication date: 29/12/2010.

6. Casimiro-Garcia A, Trujillo JI, Vajdos F, Juba B, Banker ME, Aulabaugh A, Balbo P, Bauman J, Chrencik J, Coe JW et al.. (2018) Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. J Med Chem, 61 (23): 10665-10699. [PMID:30423248]

7. Chang Y, Min J, Jarusiewicz JA, Actis M, Yu-Chen Bradford S, Mayasundari A, Yang L, Chepyala D, Alcock LJ, Roberts KG et al.. (2021) Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood, 138 (23): 2313-2326. [PMID:34110416]

8. Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, Hall T, Weinberg RA, Gormley JA, Williams JM, Day JE et al.. (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol, 400 (3): 413-33. [PMID:20478313]

9. Clark JD, Flanagan ME, Telliez JB. (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem, 57 (12): 5023-38. [PMID:24417533]

10. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U. (2014) The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther, 351 (3): 538-48. [PMID:25253883]

11. Dahlgren M, Greenwood JR, Harriman GC, Kennedy-Smith JJ, Masse CE, Romero DL, Shelley M, Wester RT. (2016) Tyk2 inhibitors and uses thereof. Patent number: WO2016138352A1. Assignee: Nimbus Lakshmi, Inc.. Priority date: 27/02/2015. Publication date: 01/09/2016.

12. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]

13. Dengler HS, Wu X, Peng I, Rinderknecht CH, Kwon Y, Suto E, Kohli PB, Liimatta M, Barrett K, Lloyd J et al.. (2018) Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma. Sci Transl Med, 10 (468): eaao2151. [PMID:30463918]

14. Drewry DH, Annor-Gyamfi JK, Wells CI, Pickett JE, Dederer V, Preuss F, Mathea S, Axtman AD. (2022) Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration. J Med Chem, 65 (2): 1313-1328. [PMID:34333981]

15. Elsayed MSA, Nielsen JJ, Park S, Park J, Liu Q, Kim CH, Pommier Y, Agama K, Low PS, Cushman M. (2018) Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series. J Med Chem, 61 (23): 10440-10462. [PMID:30460842]

16. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA, 104 (51): 20523-8. [PMID:18077363]

17. Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A et al.. (2018) Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem, 61 (19): 8597-8612. [PMID:30113844]

18. Gerstenberger BS, Ambler C, Arnold EP, Banker ME, Brown MF, Clark JD, Dermenci A, Dowty ME, Fensome A, Fish S et al.. (2020) Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem, 63 (22): 13561-13577. [PMID:32787094]

19. Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, Tan YC, Hu C, Jayaraman R, William AD et al.. (2012) TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia, 26 (2): 236-43. [PMID:21860433]

20. Hanan EJ, Liang J, Wang X, Blake RA, Blaquiere N, Staben ST. (2020) Monomeric Targeted Protein Degraders. J Med Chem, 63 (20): 11330-11361. [PMID:32352776]

21. Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA et al.. (2012) Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. J Med Chem, 55 (22): 10090-107. [PMID:23061660]

22. He X, Chen X, Zhang H, Xie T, Ye XY. (2019) Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018). Expert Opin Ther Pat, 29 (2): 137-149. [PMID:30621465]

23. Hudson R, Kozak J, Fatheree PR, Podesto DD, Brandt GEL, Fleury M, Beausoleil A-M, Huang X, Thalladi VR. (2016) Naphthyridine compounds as jak kinase inhibitors. Patent number: WO2016191524A1. Assignee: Theravance Biopharma R&D. Priority date: 28/05/2015. Publication date: 01/12/2016.

24. Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, Maeda H, Togi S, Shimoda K, Oritani K et al.. (2014) Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol, 26 (5): 257-67. [PMID:24345760]

25. Ito M, Yamazaki S, Yamagami K, Kuno M, Morita Y, Okuma K, Nakamura K, Chida N, Inami M, Inoue T et al.. (2017) A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci, 133 (1): 25-33. [PMID:28117214]

26. Jones P, Storer RI, Sabnis YA, Wakenhut FM, Whitlock GA, England KS, Mukaiyama T, Dehnhardt CM, Coe JW, Kortum SW et al.. (2017) Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J Med Chem, 60 (2): 767-786. [PMID:27983835]

27. Koudriakova T, Kreutter K, Leonard K, Rizzolio M, Smith RC, Tichenor MS, Wang A. (2018) Small molecule inhibitors of the JAK family of kinases. Patent number: WO2018112379A1. Assignee: Janssen Pharmaceutica. Priority date: 16/12/2016. Publication date: 21/06/2018.

28. Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski JS, Khan J, Ruzanov M, Strnad J, Zupa-Fernandez A et al.. (2021) Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem, 64 (1): 677-694. [PMID:33370104]

29. Liu C, Lin J, Moslin R, Tokarski JS, Muckelbauer J, Chang C, Tredup J, Xie D, Park H, Li P et al.. (2019) Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. ACS Med Chem Lett, 10 (3): 383-388. [PMID:30891145]

30. Long DD, Smith C, Thompson C. (2020) DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS. Patent number: WO/2020/051105. Assignee: THERAVANCE BIOPHARMA. Priority date: 04/09/2018. Publication date: 12/03/2020.

31. Malerich JP, Lam JS, Hart B, Fine RM, Klebansky B, Tanga MJ, D'Andrea A. (2010) Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. Bioorg Med Chem Lett, 20 (24): 7454-7. [PMID:21106455]

32. Masse CE, Greenwood JR, Mondal S, Cowen SD, McLean TH. (2019) Tyk2 inhibitors and uses thereof. Patent number: US20190256519A1. Assignee: Nimbus Discovery Inc. Priority date: 28/07/2017. Publication date: 22/08/2019.

33. Mohan R, Nuss J, Harris J, Yuan S. (2021) Tyk2 pseudokinase ligands. Patent number: US20210139486A1. Assignee: Ventyx Biosciences Inc. Priority date: 05/11/2020. Publication date: 13/05/2021.

34. Moslin R, Gardner D, Santella J, Zhang Y, Duncia JV, Liu C, Lin J, Tokarski JS, Strnad J, Pedicord D et al.. (2017) Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. Medchemcomm, 8 (4): 700-712. DOI: 10.1039/C6MD00560H [PMID:30108788]

35. Moslin RM, Weinstein DS, Wrobleski ST, Tokarski JS, Kumar A. (2014) AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES. Patent number: WO2014074661A1. Assignee: Bristol-Myers Squibb. Priority date: 08/11/2012. Publication date: 15/05/2014.

36. Nakaya Y, Shide K, Niwa T, Homan J, Sugahara S, Horio T, Kuramoto K, Kotera T, Shibayama H, Hori K et al.. (2011) Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J, 1 (7): e29. [PMID:22829185]

37. Noji S, Hara Y, Miura T, Yamanaka H, Maeda K, Hori A, Yamamoto H, Obika S, Inoue M, Hase Y et al.. (2020) Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. J Med Chem, 63 (13): 7163-7185. [PMID:32511913]

38. Pandey A, Dietsch G, Manojveer S, Thakkar M, Duraiswamy Aj. (2023) Tyk2 inhibitors and uses thereof. Patent number: WO2023227946A1. Assignee: Sudo Biosciences Limited. Priority date: 26/05/2023. Publication date: 30/11/2023.

39. Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. (2018) Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med, 379 (14): 1313-1321. [PMID:30205746]

40. Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL et al.. (2012) Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia, 26 (2): 280-8. [PMID:22015772]

41. Qiu Q, Chi F, Zhou D, Xie Z, Liu Y, Wu H, Yin Z, Shi W, Qian H. (2023) Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers. J Med Chem, 66 (8): 5753-5773. [PMID:37057760]

42. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. (1998) How cells respond to interferons. Annu Rev Biochem, 67: 227-64. [PMID:9759489]

43. Su Q, Banks E, Bebernitz G, Bell K, Borenstein CF, Chen H, Chuaqui CE, Deng N, Ferguson AD, Kawatkar S et al.. (2020) Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. J Med Chem, 63 (9): 4517-4527. [PMID:32297743]

44. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y et al.. (2015) Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res, 64 (1): 41-51. [PMID:25387665]

45. Thoma G, Duthaler RO, Waelchli R, Hauchard A, Bruno S, Strittmatter-Keller U, Orjuela Leon A, Viebrock S, Aichholz R, Beltz K et al.. (2023) Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis. J Med Chem, 66 (3): 2161-2168. [PMID:36657024]

46. Tokarski JS, Zupa-Fernandez A, Tredup JA, Pike K, Chang C, Xie D, Cheng L, Pedicord D, Muckelbauer J, Johnson SR et al.. (2015) Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem, 290 (17): 11061-74. [PMID:25762719]

47. Tsui V, Gibbons P, Ultsch M, Mortara K, Chang C, Blair W, Pulk R, Stanley M, Starovasnik M, Williams D et al.. (2011) A new regulatory switch in a JAK protein kinase. Proteins, 79 (2): 393-401. [PMID:21117080]

48. Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N et al.. (2013) Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol, 191 (7): 3568-77. [PMID:24006460]

49. Voss JW, Camp HS, Padley RJ. (2015) Jak1 selective inhibitor and uses thereof. Patent number: WO2015061665. Assignee: Abbvie Inc.. Priority date: 24/10/2013. Publication date: 30/04/2015.

50. Wan Z, Vazquez ML. (2022) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof. Patent number: US20220009927. Assignee: Lynk Pharmaceuticals Co Ltd. Priority date: 01/11/2019. Publication date: 13/01/2022.

51. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]

52. Works MG, Yin F, Yin CC, Yiu Y, Shew K, Tran TT, Dunlap N, Lam J, Mitchell T, Reader J et al.. (2014) Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol, 193 (7): 3278-87. [PMID:25156366]

53. Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L et al.. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem, 62 (20): 8973-8995. [PMID:31318208]

54. Xiong S, Yang J, Yang M, Xiao M, Ha S, Tao W, Ma L, Ji C, Xiang H, Luo G. (2025) Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model. J Med Chem, [Epub ahead of print]. [PMID:40116635]

55. Yang T, Hu M, Chen Y, Xiang M, Tang M, Qi W, Shi M, He J, Yuan X, Zhang C et al.. (2020) N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. J Med Chem, 63 (23): 14921-14936. [PMID:33256400]

56. Zhang C, Qi W, Li Y, Tang M, Yang T, Liu K, Chen Y, Deng D, Xiang M, Chen L. (2021) Discovery of 3-(4-(2-((1 H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1 H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry,. DOI: 10.1021/acs.jmedchem.0c01468 [PMID:33593051]

57. Zhao C, Zhang Y, Zhang J, Li S, Liu M, Geng Y, Liu F, Chai Q, Meng H, Li M et al.. (2023) Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. J Med Chem, 66 (20): 14150-14174. [PMID:37796543]

How to cite this page

Janus kinase (JakA) family: tyrosine kinase 2. Last modified on 02/04/2025. Accessed on 19/07/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2269.